EUCTR2007-007086-21-ES进行中（未招募）不适用
Ensayo fase II, abierto, para evaluar la seguridad, tolerabilidad y actividad antiviral de TMC125 en niños y adolescentes infectados por el VIH-1 previamente tratados con antirretrovirales.A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents. - Pediatric trial with Intelence as an Active NNRTI Option (PIANO)
Tibotec Pharmaceuticals Limited0 个研究点目标入组 100 人开始时间: 2008年7月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria are eligible for this trial:
- •1. Male or female subjects, aged between 6 and 17 years, inclusive at signing of informed consent.
- •2. Body weight according to age within 10th to 90th percentile of the CDC growth chart for children.
- •3. Subjects (where appropriate, depending on age and local regulation) and their parent(s) or legal representative(s) willing and able to give consent. Children will be informed about the trial and asked to give assent.
- •4. Subjects with documented HIV-1 infection.
- •5. Subject can comply with the protocol requirements.
- •6. HIV-1 plasma viral load at screening visit above 1000 HIV-1 RNA copies/mL.
- •7. On a stable ART for at least 8 weeks at screening and willing to stay on that treatment until baseline.
- •Note: Stable ART should comprise of a combination of at least 2 ARVs in line with the Pediatric Treatment Guidelines.
- •8. General medical condition, in the investigator’s opinion, does not interfere with the assessments and the completion of the trial.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting 1 or more of the following criteria cannot be selected:
- •1. Evidence of resistance against TMC125 based on the resistance test performed at Screening. An up to date resistance interpretation will be provided to the investigator and can be used to determine eligibility in the trial.
- •2. Previously documented HIV-2 infection.
- •3. Use of disallowed concomitant therapy.
- •4. Life expectancy of less than 6 months, according to the judgment of the investigator.
- •5. Presence of any currently active AIDS defining illness with the following exceptions, which must be discussed with the Sponsor prior to enrolment:
- •- Stable, cutaneous Kaposi Sarcoma (i.e., no pulmonary or gastrointestinal involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the trial period;
- •- Wasting syndrome due to HIV infection if, in the investigator’s opinion, it is not actively progressive and its treatment does not require hospitalization or compromise the subject’s safety or compliance to adhere to the trial protocol procedures.
- •- An AIDS defining illness not clinically stabilized for at least 30 days will be considered as currently active.
- •- Primary and secondary prophylaxis for an AIDS defining illness is allowed in case the medication used is not part of the disallowed medication.
- •6. Any condition (including but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the subject’s safety or adherence to the protocol.
- •7. Any active clinically significant disease (e.g., tuberculosis (TB), cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator’s opinion, would compromise the subject’s safety or outcome of the trial.
- •8. Acute viral hepatitis including but not limited to A, B or C.
- •9. Subject enrolled in other clinical trials that include any blood sampling, specimen collection, or other interventional procedure. Concurrent participation in non-interventional observational trials is allowed as long as there is no impact on the objectives of this trial.
- •Note: Also during the conduct of the trial, subjects are not allowed to participate in any other clinical trial that include any blood sampling, specimen collection, or other
- •interventional procedure.
- •10. Receipt of any ARV or non-ARV investigational medication or investigational vaccine within 30 days prior to screening, except for those medications where dose
- •recommendations for children are available and for which the use was discussed with and approved by the Sponsor.
- •11. Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication (TMC125).
- •12. Pregnant or breastfeeding female.
- •13. Sexually active boys, or girls who are sexually active and able to become pregnant, not using safe and effective birth control methods or not willing to continue practicing these birth control methods during the trial and until 30 days after the end of the trial (or after the last intake of the investigational medication).
- •14. Any grade 3 or 4 toxicity according to the Division of AIDS (DAIDS) grading scale except for:
- •Grade 3 absolute neutrophil count;
- •Grade 3 platelets;
- •Asymptomatic grade 3 pancreatic amylase elevation;
- •Asymptomatic grade 3 triglyceride / cholesterol / glucose elevation;
- •Asymptomatic grade 4 triglyceride elevation.
研究者
相似试验
进行中（未招募）
1 期
safety éand efficacity of the globe 1 lentiviral vector beta AS3 modified autologous CD34 +cellsEUCTR2018-001968-33-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)10
进行中（未招募）
1 期
Ensayo Clínico para estudiar la validez y seguridad del plasma rico en plaquetas en úlceras de extremidades inferiores.lcer that does not heal after being administered the optimal basic care after a period of six weeks.MedDRA version: 19.1Level: PTClassification code 10050502Term: Neuropathic ulcerSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.1Level: PTClassification code 10012679Term: Diabetic neuropathic ulcerSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.1Level: HLTClassification code 10040796Term: Skin and subcutaneous tissue ulcerationsSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-002836-42-ESAsociación Instituto de Investigación Sanitaria BioCruces
进行中（未招募）
不适用
Estudio fase II de seguridad, abierto, no controlado, multicéntrico con BAY 73-4506 en pacientes con carcinoma hepatocelular (HCC) (An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC))EUCTR2009-012570-13-ESBayer HealthCare AG30
进行中（未招募）
1 期
Phase II study with Cabozantinib in patients with RET positive NSCLCAdvanced RET-rearranged non-small cell lung cancerMedDRA version: 21.1Level: LLTClassification code 10064049Term: Lung adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002948-88-ITALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA25
进行中（未招募）
1 期
This is an open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic hepatitis B virus (HBV) infection.Chronic HBV-infected, HBeAg-negative subjects, who are non-cirrhotic and meet the cohort-specific criteria. Criteria for the planned cohorts are as follows:Cohort 1 Subjects who have been on NUC treatment for =3 years, have HBsAg <1000 IU at Baseline, and are planning to discontinue NUC therapyCohort 2 Subjects who have been suppressed on a NUC for =1 year, and have HBV DNA below LLOQ, and are planning to continue NUC therapyEUCTR2019-000896-17-GBSpring Bank Pharmaceuticals, Inc.60